ASCENTIA BIOMEDICAL ANNOUNCES OPTION AGREEMENT WITH UNIVERSITY OF WASHINGTON FOR ANTI-CANCER COMPOUND

Ascentia Biomedical Corporation, a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces an option agreement with the University of Washington, Seattle, WA for a family of novel, powerful compounds to be developed for the treatment of serious human diseases. One compound has already shown repeated efficacy in blocking tumors in a relevant, pre-clinical model of breast cancer.

Yahoo News (http://biz.yahoo.com/prnews/050815/dam009.html?.v=17)